Tuis8QQ • FRA
add
AbCellera Biologics Inc
Vorige sluiting
€2,22
Dagwisseling
€2,25 - €2,25
Jaarwisseling
€1,70 - €3,91
Markkapitalisasie
768,81 m USD
Gemiddelde volume
275,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 5,05 m | -44,98% |
Bedryfskoste | -271,00 k | -101,02% |
Netto inkomste | -34,21 m | 27,44% |
Netto winsgrens | -677,43 | -31,88% |
Wins per aandeel | -0,12 | 25,00% |
EBITDA | -26,04 m | 55,50% |
Effektiewe belastingkoers | 26,95% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 625,61 m | -17,75% |
Totale bates | 1,36 mjd | -8,57% |
Totale aanspreeklikheid | 304,47 m | -9,32% |
Totale ekwiteit | 1,06 mjd | — |
Uitstaande aandele | 297,99 m | — |
Prys om te bespreek | 0,62 | — |
Opbrengs op bates | -7,40% | — |
Opbrengs op kapitaal | -8,97% | — |
Kontantvloei
Netto kontantverandering
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -34,21 m | 27,44% |
Kontant van bedrywe | -8,00 m | 59,21% |
Kontant van beleggings | 35,70 m | 246,79% |
Kontant van finansiering | 4,14 m | 10,01% |
Netto kontantverandering | 29,68 m | 175,92% |
Beskikbare kontantvloei | -72,44 m | -28 861,47% |
Meer oor
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
HUB
Gestig
2012
Hoofkwartier
Webwerf
Werknemers
596